NCT02699606 2025-04-27A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaJanssen Research & Development, LLCPhase 2 Completed35 enrolled
NCT01703481 2025-02-03A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaJanssen Research & Development, LLCPhase 1 Completed188 enrolled
NCT04125693 2022-04-01Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyBayerPhase 2 Completed1 enrolled